| Literature DB >> 34795671 |
Jan-Hendrik Schroeder1, Luke B Roberts1, Katrin Meissl2, Jonathan W Lo1,3, Dominika Hromadová2, Kelly Hayes4, Tomasz Zabinski1, Emily Read1,5,6, Catarina Moreira Heliodoro1, Rita Reis1, Jane K Howard6, Richard K Grencis4, Joana F Neves1, Birgit Strobl2, Graham M Lord1,4.
Abstract
Innate lymphoid cells (ILC) play a significant role in the intestinal immune response and T-bet+ CD127+ group 1 cells (ILC1) have been linked to the pathogenesis of human inflammatory bowel disease (IBD). However, the functional importance of ILC1 in the context of an intact adaptive immune response has been controversial. In this report we demonstrate that induced depletion of T-bet using a Rosa26-Cre-ERT2 model resulted in the loss of intestinal ILC1, pointing to a post-developmental requirement of T-bet expression for these cells. In contrast, neither colonic lamina propria (cLP) ILC2 nor cLP ILC3 abundance were altered upon induced deletion of T-bet. Mechanistically, we report that STAT1 or STAT4 are not required for intestinal ILC1 development and maintenance. Mice with induced deletion of T-bet and subsequent loss of ILC1 were protected from the induction of severe colitis in vivo. Hence, this study provides support for the clinical development of an IBD treatment based on ILC1 depletion via targeting T-bet or its downstream transcriptional targets.Entities:
Keywords: ILCs; T-bet; innate lymphoid cells; intestinal inflammation; mucosal homeostasis 4
Mesh:
Substances:
Year: 2021 PMID: 34795671 PMCID: PMC8594445 DOI: 10.3389/fimmu.2021.760198
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Induced T-bet depletion in vivo causes complete loss of intestinal ILC1. ILC were isolated from tamoxifen-treated Tbx21 and Tbx21 Δmice for flow cytometry analysis 21 days after the first injection of tamoxifen. (A, B) cLP and SI LP ILC1 were analysed as live CD45+ Lin- CD127+ NKp46+ NK1.1+ leukocytes and (B) the percentage fold change of NKp46+ NK1.1+ ILC of total CD127+ ILC in the Tbx21 Δ mice in comparison to the Tbx21 controls was determined (n=3). Intestinal IEL ILC were isolated from tamoxifen-treated Tbx21 and Tbx21 Δmice for flow cytometry analysis. IEL ILC1 were analysed as live CD45+ Lin- NKp46+ NK1.1+ leukocytes. (C, D) Colon and SI IEL ILC1, their cellularity and expression of (E) NK1.1 and (F) NKp46 are shown (n=3). Tamoxifen-pretreated Tbx21 and Tbx21 Δ mice were infected with ( rodentium. cLP leukocytes isolated at day 6 post infection were re-stimulated with PMA and ionomycin for 3 hours prior to flow cytometry analysis. (G) Flow cytometry analysis of IFNγ, IL-17A and IL-13 expression by live CD45+ Lin- CD127+ cLP ILC and (H) statistical analysis of cytokine expression are shown (n=4). ****p < 0.0001, ***p < 0.001, *p < 0.05, ns, non-significant.
Figure 2Induced T-bet depletion in vivo does not alter cellularity of cLP ILC3 and ILC2. Tbx21 and Tbx21 Δ mice were treated with tamoxifen and flow cytometry analysis on intestinal ILC was performed 21 days after the first injection of tamoxifen. (A) Flow cytometry analyses of cLP ILC2 from Tbx21 and Tbx21 Δ mice and (B) the percentage of cLP ILC2 from total CD127+ ILC are shown (n=4). (C) Frequency of RORγt+ ILC (ILC3) among CD127+ ILC and (D) ILC3 cellularity per colon are demonstrated. (E) cLP NKp46+, CCR6+ and NKp46- CCR6- double negative (DN) ILC3 were analysed as live CD45+ Lin- CD127+ RORγt+ leukocytes. (F) Percentage of NKp46+, DN and CCR6+ ILC3 among ILC3 in Tbx21 and Tbx21 Δ mice are outlined (n=3). (G) RORγt and (H) CD127 expression geometric median of fluorescence intensity (gMFI) in NKp46+, NKp46- CCR6- DN and CCR6+ ILC3 from Tbx21 and Tbx21 Δ mice are illustrated (n=3). (I) gMFI of NKp46 expression fold change expression in in cLP NKp46+ ILC3 from Tbx21 and Tbx21 Δ mice are shown (n=3). *p < 0.05.
Figure 3Surface marker expression in ILC1 is altered upon induced deletion of T-bet. cLP leukocytes were isolated from tamoxifen-treated Tbx21 and Tbx21 Δmice for flow cytometry analysis 14 days after the first injection of tamoxifen. (A) Flow cytometry analysis of NKp46+ NK1.1+ cLP ILC and (B) respective frequency statistical analysis among CD127+ ILC are outlined. (C) cLP ILC1 were analysed as CD127+ KLRG1- RORγt- NKp46+ NK1.1+/- ILC (ILC1) and (D) the cell counts per colon in Tbx12 and Tbx21 Δ mice were determined for ILC1 and CD127+ ILC (n=3). (E) gMFI of NKp46, CD122 and NK1.1 surface expression in Tbx21 and Tbx21 Δ ILC1 defined as CD127+ KLRG1- RORγt- NKp46+ NK1.1+ ILC was evaluated statistically (n=3). (F) Flow cytometry and statistical analyses of T-bet protein expression in Tbx21 and Tbx21 ΔcLP ILC1 and NKp46+ ILC3 defined as CD127+ RORγt+ NKp46+ ILC are presented (n=3). cLP NKp46+ NK1.1+ CD127+ ILC were analysed in WT, (G) Stat1 or (H) Stat4 mice and (I) the percentage of these cells within the CD127+ ILC population was analysed (n=4). (J) IFNγ percentual expression in cLP CD127+ ILC from Stat1 and Stat4 mice upon a 4 hour stimulation with PMA and ionomycin is shown (n=4). ***p < 0.001, *p < 0.05.
Figure 4Induced T-bet depletion causes milder DSS-elicited colitis. Mice received DSS in the drinking water for clinical investigation. (A, B) Tbx21 and Tbx21 Δ mice pre-treated with tamoxifen were exposed to 3% DSS in the drinking water for 5 days followed by a period of rest (n=8-14). Control mice receiving FW without DSS were included in the study. (A) Daily percentual weight change to body weight at the start and (B) daily diarrhoea scoring are illustrated. (C–F) cLP leukocytes were isolated 2 days after DSS withdrawal and re-stimulated with PMA and ionomycin for 3 hours prior to analysis. (C) Flow cytometry analysis of IFNγ, IL-17A and IL-13 expression in live CD45+ Lin- CD127+ ILC and (D) statistical analysis of cytokine expression are shown (n=3-4). IFNγ expression in (E) CD90.2+ and CD90.2- non-ILC leukocytes and (F) live CD45+ Lin- and Lin+ leukocytes in addition to respective statistical analyses are shown (n=3-4). *p < 0.05, ns, non-significant.
Antibody clones and distributors.
| Antibody | Clone | Company |
|---|---|---|
| B220 | RA3-6B2 | eBioscience |
| CCR6 | 29-2L17 | eBioscience |
| CD103 | 2E 7 | Biolegend |
| CD11b | M1/70 | eBioscience |
| CD122 | TM-β1 | eBioscience |
| CD127 | A7R34 | eBioscience |
| CD19 | 1D3 | eBioscience |
| CD25 | PC61 | Biolegend |
| CD3 | 17A2 | eBioscience |
| CD3 ( | 142-2C11 | Biolegend |
| CD4 | RM4-5 | Biolegend |
| CD44 | IL7 | Biolegend |
| CD45 | 30-F11 | Invitrogen |
| CD45.2 ( | 104 | Biolegend |
| CD5 | 53-7.3 | eBioscience |
| CD62L | Mel-14 | Biolegend |
| CD8a | 53-6.7 | BD |
| CD90.2 | 29A1.4 | eBioscience |
| Eomes | Dan11Mag | Biolegend |
| FcϵRI | MAR | eBioscience |
| FoxP3 | FJK-16s | eBioscience |
| GATA3 | 823 | R&D |
| Gr-1 | RB6-8C5 | eBioscience |
| ICOS | C398.4 | eBioscience |
| IFNγ | XMG1.2 | eBioscience |
| IFNγ ( | XMG1.2 | Biolegend |
| IFNγ ( | eF450 | eBioscience |
| IL-13 | eBio13A | eBioscience |
| IL-17A | PAJ-17R | eBioscience |
| IL-17A ( | 18H10.1 | Biolegend |
| IL-4 | 11B11 | Biolegend |
| Ki67 | 20Raj1 | eBioscience |
| KLRG1 | 2F1 | eBioscience |
| NK1.1 | PK136 | Biolegend |
| NKp46 | 29A1.4 | eBioscience |
| RORγt | AFKJS-9 | eBioscience |
| RORγt ( | Q31-378 | R&D |
| RORγt ( | AFKJS-9 | Invitrogen |
| T-bet | 4B10 | Invitrogen |
| Ter119 | TER-119 | eBioscience |